PT  - JOURNAL ARTICLE
AU  - A.N. Wallace
AU  - A. Tomasian
AU  - D. Vaswani
AU  - R. Vyhmeister
AU  - R.O. Chang
AU  - J.W. Jennings
TI  - Radiographic Local Control of Spinal Metastases with Percutaneous Radiofrequency Ablation and Vertebral Augmentation
AID  - 10.3174/ajnr.A4595
DP  - 2016 Apr 01
TA  - American Journal of Neuroradiology
PG  - 759--765
VI  - 37
IP  - 4
4099  - http://www.ajnr.org/content/37/4/759.short
4100  - http://www.ajnr.org/content/37/4/759.full
SO  - Am. J. Neuroradiol.2016 Apr 01; 37
AB  - BACKGROUND AND PURPOSE: Combination radiofrequency ablation and vertebral augmentation is an emerging minimally invasive therapy for patients with metastatic spine disease who have not responded to or have contraindications to radiation therapy. The purpose of this study was to evaluate the rate of radiographic local control of spinal metastases treated with combination radiofrequency ablation and vertebral augmentation.MATERIALS AND METHODS: We retrospectively reviewed our tumor ablation database for all patients who underwent radiofrequency ablation and vertebral augmentation of spinal metastases between April 2012 and July 2014. Tumors treated in conjunction with radiation therapy were excluded. Tumor characteristics, procedural details, and complications were recorded. Posttreatment imaging was reviewed for radiographic evidence of tumor progression.RESULTS: Fifty-five tumors met study inclusion criteria. Radiographic local tumor control rates were 89% (41/46) at 3 months, 74% (26/35) at 6 months, and 70% (21/30) at 1 year after treatment. Clinical follow-up was available in 93% (51/55) of cases. The median duration of clinical follow-up was 34 weeks (interquartile range, 15–89 weeks), during which no complications were reported and no patients had clinical evidence of metastatic spinal cord compression at the treated levels.CONCLUSIONS: Combination radiofrequency ablation and vertebral augmentation appears to be an effective treatment for achieving local control of spinal metastases. A prospective clinical trial is now needed to replicate these results.RFAradiofrequency ablation